{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T01:12:15Z","timestamp":1787879535223,"version":"build-2784847793"},"reference-count":86,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T00:00:00Z","timestamp":1698192000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100022606","name":"Almirall","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100022606","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"abstract":"<jats:p>The evidence on treating older patients with psoriasis with modern biologics is scarce. This study compared the efficacy and safety of tildrakizumab among younger and older patients with psoriasis (&lt;\u200965\/\u2265\u200965 years) in a post hoc analysis of 2 phase III trials (reSURFACE1\/2, n\u2009=\u20091,862). Tildrakizumab 100 mg\/200 mg was administered at weeks 0\/4\/every 12 weeks thereafter. At week 28, patients with \u2265\u200975% improvement in baseline Psoriasis Area and Severity Index (PASI75) in reSURFACE1 were re-randomized to the same tildrakizumab dose or placebo; in reSURFACE2, PASI75 responders to 200 mg were re-randomized to tildrakizumab 100 mg or 200 mg; PASI75 responders to 100 mg maintained their dose. At weeks 64\/52 (reSURFACE1\/2), PASI50 responders entered an extension period (weeks 256\/244). Outcomes were proportion of patients with PASI\u2009&lt;\u20093, Dermatology Life Quality Index (DLQI) 0\/1, comorbidities, comedication, and side-effects. The proportion of patients with a PASI\u2009&lt;\u20093 was similar and maintained (tildrakizumab 100 mg and 200 mg, week 244: 83.3% and 84.1%\/92.3% and 100.0%); DLQI 0\/1 proportions at week 52 were 66.8% and 72.0%\/68.3% and 81.3%. Comorbidity and comedication were more common in older patients. The safety profile of tildrakizumab appeared favourable in both groups. Tildrakizumab in patients \u2265\u200965 years appears effective and safe in long-term psoriasis management. These findings might assist treatment selection and overcome treatment reluctance.<\/jats:p>","DOI":"10.2340\/actadv.v103.17752","type":"journal-article","created":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T12:26:39Z","timestamp":1698236799000},"page":"adv17752","source":"Crossref","is-referenced-by-count":15,"title":["Efficacy and Safety of Tildrakizumab in Older Patients: Pooled Analyses of Two Randomized Phase III Clinical Trials (reSURFACE 1 and reSURFACE 2) Through 244 Weeks"],"prefix":"10.2340","volume":"103","author":[{"given":"Elke L. M.","family":"Ter Haar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juul M. P. A.","family":"Van den Reek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Gaarn Du Jardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almudena","family":"Barbero-Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke M. G. J.","family":"De Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satish F. K.","family":"Lubeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2023,10,25]]},"reference":[{"key":"40255","doi-asserted-by":"crossref","unstructured":"Sewerin P, Brinks R, Schneider M, Haase I, Vordenb\u00e4umen S. Prevalence and incidence of psoriasis and psoriatic arthritis. Ann Rheum Dis 2019; 78: 286-287.","DOI":"10.1136\/annrheumdis-2018-214065"},{"key":"40256","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1136\/annrheumdis-2018-214065","DOI":"10.1136\/annrheumdis-2018-214065"},{"key":"40257","doi-asserted-by":"crossref","unstructured":"Kwon HH, Kwon IH, Youn JI. Clinical study of psoriasis occurring over the age of 60 years: is elderly-onset psoriasis a distinct subtype? Int J Dermatol 2012; 51: 53-58.","DOI":"10.1111\/j.1365-4632.2011.04979.x"},{"key":"40258","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1365-4632.2011.04979.x","DOI":"10.1111\/j.1365-4632.2011.04979.x"},{"key":"40259","unstructured":"NIH. World's older population grows dramatically. National Institute on Aging. [Accessed 2022 July 22]. Available from: https:\/\/www.nia.nih.gov\/news\/worlds-older-population-grows-dramatically."},{"key":"40260","doi-asserted-by":"crossref","unstructured":"Phan C, Sigal ML, Est\u00e8ve E, Reguiai Z, Barth\u00e9l\u00e9my H, Beneton N, et al. Psoriasis in the elderly: epidemiological and clinical aspects, and evaluation of patients with very late onset psoriasis. J Eur Acad Dermatol Venereol 2016; 30: 78-82.","DOI":"10.1111\/jdv.12850"},{"key":"40261","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.12850","DOI":"10.1111\/jdv.12850"},{"key":"40262","doi-asserted-by":"crossref","unstructured":"P\u00e9rez-Jover V, Mira JJ, Carratala-Munuera C, Gil-Guillen VF, Basora J, L\u00f3pez-Pineda A, et al. Inappropriate use of medication by elderly, polymedicated, or multipathological patients with chronic diseases. Int J Environ Res Public Health 2018; 15: 310.","DOI":"10.3390\/ijerph15020310"},{"key":"40263","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3390\/ijerph15020310","DOI":"10.3390\/ijerph15020310"},{"key":"40264","doi-asserted-by":"crossref","unstructured":"Banerjee A, Mbamalu D, Ebrahimi S, Khan AA, Chan TF. The prevalence of polypharmacy in elderly attenders to an emergency department - a problem with a need for an effective solution. Int J Emerg Med 2011; 4: 22.","DOI":"10.1186\/1865-1380-4-22"},{"key":"40265","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1186\/1865-1380-4-22","DOI":"10.1186\/1865-1380-4-22"},{"key":"40266","doi-asserted-by":"crossref","unstructured":"Davies EA, O'Mahony MS. Adverse drug reactions in special populations - the elderly. Br J Clin Pharmacol 2015; 80: 796-807.","DOI":"10.1111\/bcp.12596"},{"key":"40267","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bcp.12596","DOI":"10.1111\/bcp.12596"},{"key":"40268","doi-asserted-by":"crossref","unstructured":"van Winden MEC, Ter Haar ELM, Groenewoud JMM, van de Kerkhof PCM, de Jong EMGJ, Lubeek SFK. Quality of life, treatment goals, preferences and satisfaction in older adults with psoriasis: a patient survey comparing age groups. Br J Dermatol 2021; 184: 759-762.","DOI":"10.1111\/bjd.19665"},{"key":"40269","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.19665","DOI":"10.1111\/bjd.19665"},{"key":"40270","doi-asserted-by":"crossref","unstructured":"Ricceri F, Bardazzi F, Chiricozzi A, Dapavo P, Ferrara F, Mugheddu C, et al. Elderly psoriatic patients under biological therapies: an Italian experience. J Eur Acad Dermatol Venereol 2019; 33: 143-146.","DOI":"10.1111\/jdv.15139"},{"key":"40271","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.15139","DOI":"10.1111\/jdv.15139"},{"key":"40272","unstructured":"Garber C, Plotnikova N, Au S Chung, Sorensen EP, Gottlieb A. Biologic and conventional systemic therapies show similar safety and efficacy in elderly and adult patients with moderate to severe psoriasis. J Drugs Dermatol 2015; 14: 846-852."},{"key":"40273","doi-asserted-by":"crossref","unstructured":"Schaap MJ, van Winden MEC, Seyger MMB, de Jong EMGJ, Lubeek SFK. Representation of older adults in randomized controlled trials on systemic treatment in plaque psoriasis: a systematic review. J Am Acad Dermatol 2020; 83: 412-424.","DOI":"10.1016\/j.jaad.2019.07.079"},{"key":"40274","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2019.07.079","DOI":"10.1016\/j.jaad.2019.07.079"},{"key":"40275","doi-asserted-by":"crossref","unstructured":"Haar ELM ter, Thomas SE, van den Reek JMPA, Otero ME, Njoo MD, Ossenkoppele PM, et al. Drug survival, safety, and effectiveness of biologics in older patients with psoriasis: a comparison with younger patients - a BioCAPTURE Registry study. Drugs Aging 2022; 39: 715-727.","DOI":"10.1007\/s40266-022-00961-y"},{"key":"40276","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s40266-022-00961-y","DOI":"10.1007\/s40266-022-00961-y"},{"key":"40277","doi-asserted-by":"crossref","unstructured":"Haar ELM ter, Bruin EE ten, Bronkhorst EE, Borgonjen RJ, Kleinpenning MM, Kop EN, et al. Safety assessment of conventional and biological systemic therapy in older adults with psoriasis, a real-world multicentre cohort study. Acta Derm Venereol 2022; 102: adv00805.","DOI":"10.2340\/actadv.v102.2412"},{"key":"40278","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/actadv.v102.2412","DOI":"10.2340\/actadv.v102.2412"},{"key":"40279","doi-asserted-by":"crossref","unstructured":"Ruggiero A, Fabbrocini G, Cinelli E, Ocampo Garza SS, Camela E, Megna M. Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice. Clin Exp Dermatol 2022; 47: 561-567.","DOI":"10.1111\/ced.14979"},{"key":"40280","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/ced.14979","DOI":"10.1111\/ced.14979"},{"key":"40281","doi-asserted-by":"crossref","unstructured":"Kolli SS, Gabros SD, Pona A, Cline A, Feldman SR. Tildrakizumab: a review of phase II and III clinical trials. Ann Pharmacother 2019; 53: 413-418.","DOI":"10.1177\/1060028018809522"},{"key":"40282","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1177\/1060028018809522","DOI":"10.1177\/1060028018809522"},{"key":"40283","doi-asserted-by":"crossref","unstructured":"Reich K, Papp K, Blauvelt A, Tyring S, Sinclair R, Tha\u00e7i D, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. The Lancet 2017; 390: 276-288.","DOI":"10.1016\/S0140-6736(17)31279-5"},{"key":"40284","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0140-6736(17)31279-5","DOI":"10.1016\/S0140-6736(17)31279-5"},{"key":"40285","doi-asserted-by":"crossref","unstructured":"Thaci D, Piaserico S, Warren RB, Gupta AK, Cantrell W, Draelos Z, et al. Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2). Br J Dermatol 2021; 185: 323-334.","DOI":"10.1111\/bjd.19866"},{"key":"40286","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.19866","DOI":"10.1111\/bjd.19866"},{"key":"40287","doi-asserted-by":"crossref","unstructured":"Reich K, Warren RB, Iversen L, Puig L, Pau-Charles I, Igarashi A, et al. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks. Br J Dermatol 2020; 182: 605-617.","DOI":"10.1111\/bjd.18232"},{"key":"40288","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.18232","DOI":"10.1111\/bjd.18232"},{"key":"40289","doi-asserted-by":"crossref","unstructured":"Langenbruch A, Radtke MA, Gutknecht M, Augustin M. Does the Dermatology Life Quality Index (DLQI) underestimate the disease-specific burden of psoriasis patients? J Eur Acad Dermatol Venereol 2019; 33: 123-127.","DOI":"10.1111\/jdv.15226"},{"key":"40290","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.15226","DOI":"10.1111\/jdv.15226"},{"key":"40291","doi-asserted-by":"crossref","unstructured":"Rencz F, Gul\u00e1csi L, P\u00e9ntek M, Szegedi A, Remenyik \u00c9, Bata-Cs\u00f6rg\u0151 Z, et al. DLQI-R scoring improves the discriminatory power of the Dermatology Life Quality Index in patients with psoriasis, pemphigus and morphea. Br J Dermatol 2020; 182: 1167-1175.","DOI":"10.1111\/bjd.18435"},{"key":"40292","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.18435","DOI":"10.1111\/bjd.18435"},{"key":"40293","doi-asserted-by":"crossref","unstructured":"Rencz F, Gul\u00e1csi L, P\u00e9ntek M, Po\u00f3r A k., S\u00e1rdy M, Holl\u00f3 P, et al. Proposal of a new scoring formula for the Dermatology Life Quality Index in psoriasis. Br J Dermatol 2018; 179: 1102-1108.","DOI":"10.1111\/bjd.16927"},{"key":"40294","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.16927","DOI":"10.1111\/bjd.16927"},{"key":"40295","doi-asserted-by":"crossref","unstructured":"Bakirtzi K, Sotiriou E, Papadimitriou I, Sideris N, Vakirlis E, Lallas A, et al. Elderly patients with psoriasis: long-term efficacy and safety of modern treatments. J Dermatol Treat 2022; 33: 1339-1342.","DOI":"10.1080\/09546634.2020.1809623"},{"key":"40296","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/09546634.2020.1809623","DOI":"10.1080\/09546634.2020.1809623"},{"key":"40297","doi-asserted-by":"crossref","unstructured":"Gheno R, Cepparo JM, Rosca CE, Cotten A. Musculoskeletal disorders in the elderly. J Clin Imaging Sci 2012; 2: 39.","DOI":"10.4103\/2156-7514.99151"},{"key":"40298","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.4103\/2156-7514.99151","DOI":"10.4103\/2156-7514.99151"},{"key":"40299","doi-asserted-by":"crossref","unstructured":"Bechtold M, Palmer J, Valtos J, Iasiello C, Sowers J. Metabolic syndrome in the elderly. Curr Diab Rep 2006; 6: 64-71.","DOI":"10.1007\/s11892-006-0054-3"},{"key":"40300","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s11892-006-0054-3","DOI":"10.1007\/s11892-006-0054-3"},{"key":"40301","doi-asserted-by":"crossref","unstructured":"Writing Groups Members, Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, et al. Heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation 2010; 121: e46-e215.","DOI":"10.1161\/CIRCULATIONAHA.109.192667"},{"key":"40302","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.192667","DOI":"10.1161\/CIRCULATIONAHA.109.192667"},{"key":"40303","doi-asserted-by":"crossref","unstructured":"Gisondi P, Fostini AC, Foss\u00e0 I, Girolomoni G, Targher G. Psoriasis and the metabolic syndrome. Clin Dermatol 2018; 36: 21-28.","DOI":"10.1016\/j.clindermatol.2017.09.005"},{"key":"40304","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.clindermatol.2017.09.005","DOI":"10.1016\/j.clindermatol.2017.09.005"},{"key":"40305","unstructured":"Frieder J, Ryan C. Psoriasis and cardiovascular disorders. G Ital Dermatol Venereol 2016; 151: 678-693."},{"key":"40306","doi-asserted-by":"crossref","unstructured":"Cuesta-Montero L, Belinch\u00f3n I. Connective tissue diseases and psoriasis. Actas Dermosifiliogr 2011; 102: 487-497.","DOI":"10.1016\/j.adengl.2011.03.003"},{"key":"40307","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ad.2011.03.002","DOI":"10.1016\/j.ad.2011.03.002"},{"key":"40308","unstructured":"European Medicines Agency (EMA). [Accessed 2022 Feb 10]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ilumetri-epar-product-information_en.pdf."},{"key":"40309","doi-asserted-by":"crossref","unstructured":"Armstrong AW, Puig L, Joshi A, Skup M, Williams D, Li J, et al. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol 2020; 156: 258-269.","DOI":"10.1001\/jamadermatol.2019.4029"},{"key":"40310","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jamadermatol.2019.4029","DOI":"10.1001\/jamadermatol.2019.4029"},{"key":"40311","doi-asserted-by":"crossref","unstructured":"Barbieri JS, Shin DB, Syed MN, Takeshita J, Gelfand JM. Evaluation of the frequency of 'not relevant' responses on the dermatology life quality index by sociodemographic characteristics of patients with psoriasis. JAMA Dermatol 2020; 156: 446-450.","DOI":"10.1001\/jamadermatol.2019.4659"},{"key":"40312","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jamadermatol.2019.4659","DOI":"10.1001\/jamadermatol.2019.4659"},{"key":"40313","doi-asserted-by":"crossref","unstructured":"Barbieri JS, Gelfand JM. Responsiveness of the EuroQol 5-dimension 3-level instrument, Dermatology Life Quality Index (DLQI) and DLQI-relevant for patients with psoriasis in the U.S.A. Br J Dermatol 2019; 181: 1088-1090.","DOI":"10.1111\/bjd.18142"},{"key":"40314","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.18142","DOI":"10.1111\/bjd.18142"},{"key":"40315","doi-asserted-by":"crossref","unstructured":"Rencz F, Po\u00f3r AK, P\u00e9ntek M, Holl\u00f3 P, K\u00e1rp\u00e1ti S, Gul\u00e1csi L, et al. A detailed analysis of 'not relevant' responses on the DLQI in psoriasis: potential biases in treatment decisions. J Eur Acad Dermatol Venereol 2018; 32: 783-790.","DOI":"10.1111\/jdv.14676"},{"key":"40316","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.14676","DOI":"10.1111\/jdv.14676"},{"key":"40317","doi-asserted-by":"crossref","unstructured":"Barbieri JS, Gelfand JM. Influence of 'not relevant' responses on the Dermatology Life Quality Index (DLQI) for patients with psoriasis in the United States. JAMA Dermatol 2019; 155: 743-745.","DOI":"10.1001\/jamadermatol.2018.5655"},{"key":"40318","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jamadermatol.2018.5655","DOI":"10.1001\/jamadermatol.2018.5655"},{"key":"40319","doi-asserted-by":"crossref","unstructured":"Rencz F, Gergely H, Wikonkal N, G\u00e1sp\u00e1r K, P\u00e9ntek M, Gulacsi L, et al. Dermatology Life Quality Index (DLQI) score bands are applicable to DLQI-Relevant (DLQI-R) scoring. J Eur Acad Dermatol Venereol 2020; 34: e484-e486.","DOI":"10.1111\/jdv.16398"},{"key":"40320","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.16398","DOI":"10.1111\/jdv.16398"},{"key":"40321","doi-asserted-by":"crossref","unstructured":"Rencz F, Gul\u00e1csi L, P\u00e9ntek M, Szegedi A, Remenyik \u00c9, Bata-Cs\u00f6rg\u0151 Z, et al. DLQI-R scoring improves the discriminatory power of the Dermatology Life Quality Index in patients with psoriasis, pemphigus and morphea. Br J Dermatol 2020; 182: 1167-1175.","DOI":"10.1111\/bjd.18435"},{"key":"40322","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.18435","DOI":"10.1111\/bjd.18435"},{"key":"40323","doi-asserted-by":"crossref","unstructured":"van L\u00fcmig PPM, Driessen RJB, Berends M a. M, Boezeman JBM, van de Kerkhof PCM, de Jong EMGJ. Safety of treatment with biologics for psoriasis in daily practice: 5-year data. J Eur Acad Dermatol Venereol 2012; 26: 283-291.","DOI":"10.1111\/j.1468-3083.2011.04044.x"},{"key":"40324","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1468-3083.2011.04044.x","DOI":"10.1111\/j.1468-3083.2011.04044.x"},{"key":"40325","doi-asserted-by":"crossref","unstructured":"Howell ST, Cardwell LA, Feldman SR. Treating moderate-to-severe plaque psoriasis with guselkumab: a review of phase II and phase III trials. Ann Pharmacother 2018; 52: 380-387.","DOI":"10.1177\/1060028017743268"},{"key":"40326","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1177\/1060028017743268","DOI":"10.1177\/1060028017743268"},{"key":"40327","doi-asserted-by":"crossref","unstructured":"Wan MT, Shin DB, Winthrop KL, Gelfand JM. The risk of respiratory tract infections and symptoms in psoriasis patients treated with interleukin 17 pathway-inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic. J Am Acad Dermatol 2020; 83: 677-679.","DOI":"10.1016\/j.jaad.2020.05.035"},{"key":"40328","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2020.05.035","DOI":"10.1016\/j.jaad.2020.05.035"},{"key":"40329","doi-asserted-by":"crossref","unstructured":"Rivera R, Garc\u00eda-Doval I, Carretero G, Daud\u00e9n E, S\u00e1nchez-Carazo J, Ferr\u00e1ndiz C, et al. BIOBADADERM, the Spanish Registry of adverse events associated with biologic drugs in dermatology: first report. Actas Dermosifiliogr 2011; 102: 132-141.","DOI":"10.1016\/S1578-2190(11)70770-3"},{"key":"40330","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ad.2010.10.016","DOI":"10.1016\/j.ad.2010.10.016"},{"key":"40331","doi-asserted-by":"crossref","unstructured":"Naldi L, Mercuri SR. Epidemiology of comorbidities in psoriasis. Dermatol Ther 2010; 23: 114-118.","DOI":"10.1111\/j.1529-8019.2010.01304.x"},{"key":"40332","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1529-8019.2010.01304.x","DOI":"10.1111\/j.1529-8019.2010.01304.x"},{"key":"40333","doi-asserted-by":"crossref","unstructured":"Singh RK, Lee KM, Ucmak D, Brodsky M, Atanelov Z, Farahnik B, et al. Erythrodermic psoriasis: pathophysiology and current treatment perspectives. Psoriasis (Auckl) 2016; 6: 93-104.","DOI":"10.2147\/PTT.S101232"},{"key":"40334","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2147\/PTT.S101232","DOI":"10.2147\/PTT.S101232"},{"key":"40335","doi-asserted-by":"crossref","unstructured":"Yosipovitch G, Tang MBY. Practical management of psoriasis in the elderly: epidemiology, clinical aspects, quality of life, patient education and treatment options. Drugs Aging 2002; 19: 847-863.","DOI":"10.2165\/00002512-200219110-00003"},{"key":"40336","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2165\/00002512-200219110-00003","DOI":"10.2165\/00002512-200219110-00003"},{"key":"40337","doi-asserted-by":"crossref","unstructured":"Drerup KA, Seemann C, Gerdes S, Mrowietz U. Effective and safe treatment of psoriatic disease with the anti-IL-23p19 biologic tildrakizumab: results of a real-world prospective cohort study in nonselected patients. Dermatology (Basel, Switzerland) 2022; 238: 615-619.","DOI":"10.1159\/000519924"},{"key":"40338","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1159\/000519924","DOI":"10.1159\/000519924"},{"key":"40339","doi-asserted-by":"crossref","unstructured":"Tsianakas A, Schwichtenberg U, Pierchalla P, Hinz T, Diemert S, Korge B. Real-world effectiveness and safety of tildrakizumab in long-term treatment of plaque psoriasis: Results from the non-interventional, prospective, multicentre study TILOT. J Eur Acad Dermatol Venereol 2023; 37: 85-92.","DOI":"10.1111\/jdv.18572"},{"key":"40340","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.18572","DOI":"10.1111\/jdv.18572"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/17752\/28483","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/17752\/28483","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T12:27:00Z","timestamp":1698236820000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/17752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,25]]},"references-count":86,"URL":"https:\/\/doi.org\/10.2340\/actadv.v103.17752","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,25]]}}}